Description: Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.
Home Page: arcturusrx.com
ARCT Technical Analysis
10628 Science Center Drive
San Diego,
CA
92121
United States
Phone:
858 900 2660
Officers
| Name | Title |
|---|---|
| Mr. Joseph E. Payne M.Sc. | Founder, Pres, CEO & Director |
| Dr. Padmanabh Chivukula | Founder, Chief Scientific Officer, COO & Sec. |
| Mr. Andrew H. Sassine MBA | CFO & Director |
| Mr. Lance Kurata | Chief Legal Officer |
| Dr. Steven George Hughes M.B.A., M.D. | Strategic Clinical Advisor & Member of Scientific Advisory Board |
| Mr. Keith C. Kummerfeld CPA | VP of Fin. & Corp. Controller |
| Dr. Dushyant B. Varshney Ph.D. | Exec. VP & Chief Technology Officer |
| Mr. Deepankar Roy | Sr. Director of Investor Relations |
| Kyle Gutstadt | Sr. Analyst of Investor & PR |
| Mr. Kevin T. Skol | Sr. VP of Bus. Devel. & Alliance Management |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 2.8604 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4283 |
| Price-to-Sales TTM: | 9.3831 |
| IPO Date: | 2020-04-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 177 |